Swixx Biopharma’s acquisition financing
Arias, Fábrega & Fábrega has advised UBS Switzerland in the acquisition financing for the acquisition by Swixx Biopharma of 100% of the equity of Pharma Consulting Group S.A., the holding company of Laboratorios Biopas S.A., a well-established pharmaceutical company in Latin America.
The firm assisted UBS Switzerland with the Panamanian aspects related to a Swiss law-governed secured credit facilities agreement to finance the acquisition by Swixx Biopharma, a leading global commercial platform based in Switzerland dedicated to unlocking access to innovative medicine worldwide. The acquisition involved 100% of the equity of Pharma Consulting Group S.A., the holding company of Laboratorios Biopas S.A. This acquisition marks Swixx Biopharma's significant expansion into the Latin American market. Laboratorios Biopas is a well-established pharmaceutical company in Latin America, known for its expertise in the in-licensing, marketing, and sale of specialty pharmaceutical products.
Establishing an Ethical Wall, ARIFA’s M&A team advised Swixx Biopharma in the strategic acquisition.